India should remain on 301 ‘Priority Watch List’, says PhRMA
09-02-2016
ericsphotography / iStockphoto.com
Indian pharmaceutical companies should be encouraged to grant compulsory licences and prices of some patented medicines should be capped, an Indian government panel has said.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
India, compulsory licence, pharmaceuticals, government, drug patents, cancer, rare disease
